Literature DB >> 1715315

Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-1-dependent and -independent mechanisms.

S H Smith1, K P Rigley, R E Callard.   

Abstract

Addition of CD19 monoclonal antibodies (mAb) to highly purified tonsillar B cells resulted in homotypic adhesion and the formation of cell clusters. This response was completely blocked by antibody to LFA-1, indicating an LFA-1-dependent adhesion mechanism. In contrast, aggregate formation by B cells activated with phorbol myristate acetate (PMA) was only partially inhibited by anti-LFA-1 antibody, and those formed in response to PMA plus CD19 antibody were not inhibited at all, suggesting aggregation of activated B cells stimulated with CD19 antibody was LFA-1 independent. This was confirmed with B-cell lines. The pre-B-cell line Nalm-6 formed aggregates in response to CD19 antibody which were not inhibited with anti-LFA-1. In addition, CD19 antibody induced aggregate formation by an Epstein-Barr virus (EBV)-transformed B-cell line derived from an LFA-1-deficient donor. These results suggest that different adhesion molecules may operate at different stages of B-cell activation, and that CD19 may be important in cell-cell interactions involved in regulation of antibody responses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715315      PMCID: PMC1384545     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  12 in total

1.  CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation.

Authors:  A Pezzutto; B Dörken; P S Rabinovitch; J A Ledbetter; G Moldenhauer; E A Clark
Journal:  J Immunol       Date:  1987-05-01       Impact factor: 5.422

2.  Expression of an antigen associated with acute lymphoblastic leukemia in human leukemia-lymphoma cell lines.

Authors:  J Minowada; G Janossy; M F Greaves; T Tsubota; B I Srivastava; S Morikawa; E Tatsumi
Journal:  J Natl Cancer Inst       Date:  1978-06       Impact factor: 13.506

3.  Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19.

Authors:  J A Ledbetter; P S Rabinovitch; C H June; C W Song; E A Clark; F M Uckun
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

4.  Resting B lymphocytes can be triggered directly through the CDw40 (Bp50) antigen. A comparison with IL-4-mediated signaling.

Authors:  J Gordon; M J Millsum; G R Guy; J A Ledbetter
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

5.  Histocompatibility requirements for T cell help in specific in vitro antibody responses to influenza virus by human blood lymphocytes.

Authors:  R E Callard; C M Smith
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

6.  T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1.

Authors:  M L Dustin; T A Springer
Journal:  Nature       Date:  1989-10-19       Impact factor: 49.962

7.  Inhibition of B cell proliferation with anti-CD19 monoclonal antibodies: anti-CD19 antibodies do not interfere with early signaling events triggered by anti-IgM or interleukin 4.

Authors:  K P Rigley; R E Callard
Journal:  Eur J Immunol       Date:  1991-03       Impact factor: 5.532

8.  LFA-1 beta-chain synthesis and degradation in patients with leukocyte-adhesive proteins deficiency.

Authors:  M T Dimanche; F Le Deist; A Fischer; M A Arnaout; C Griscelli; B Lisowska-Grospierre
Journal:  Eur J Immunol       Date:  1987-03       Impact factor: 5.532

9.  CD19 is functionally and physically associated with surface immunoglobulin.

Authors:  J M Pesando; L S Bouchard; B E McMaster
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Temporal relationship between inositol polyphosphate formation and increases in cytosolic Ca2+ in quiescent 3T3 cells stimulated by platelet-derived growth factor, bombesin and vasopressin.

Authors:  E Nånberg; E Rozengurt
Journal:  EMBO J       Date:  1988-09       Impact factor: 11.598

View more
  8 in total

1.  Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner.

Authors:  Elizabeth O Lobo; Zhifang Zhang; John E Shively
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

2.  A new CD43 monoclonal antibody induces homotypic aggregation of human leucocytes through a CD11a/CD18-dependent and -independent mechanism.

Authors:  W de Smet; H Walter; L van Hove
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

3.  Globotriaosyl ceramide modulates interferon-alpha-induced growth inhibition and CD19 expression in Burkitt's lymphoma cells.

Authors:  M D Maloney; B Binnington-Boyd; C A Lingwood
Journal:  Glycoconj J       Date:  1999-12       Impact factor: 2.916

4.  Inhibition of LFA-1-dependent human B-cell aggregation induced by CD40 antibodies and interleukin-4 leads to decreased IgE synthesis.

Authors:  P Björck; S Paulie
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

5.  Homotypic adhesion of rat B cells, but not T cells, in response to cross-linking of CD48.

Authors:  D Garnett; A F Williams
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

6.  Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion.

Authors:  Y Shimizu; G A van Seventer; E Ennis; W Newman; K J Horgan; S Shaw
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

7.  CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis.

Authors:  M D Maloney; C A Lingwood
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

8.  Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin.

Authors:  S Behr; F Schriever
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.